Results 11 to 20 of about 44,703 (257)

Clinical Images: Erdheim-Chester disease presenting with fever, enlarged lymph nodes, and monoallelic BRAF (V600E) mutation. [PDF]

ACR Open Rheumatol
ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Gan L, Zhang Q, Yan H, Bai H, Tang X.
europepmc   +2 more sources

CRAF R391W is a melanoma driver oncogene. [PDF]

, 2016
Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known.
Atefi, Mohammad, Avramis, Earl, Chmielowski, Bartosz, Friedman, Michael, Graeber, Thomas G, Lassen, Amanda, Le, Allison, Lomova, Anastasia, Ng, Charles, Ribas, Antoni, Titz, Bjoern, Tsoi, Jennifer   +11 more
core   +7 more sources

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Evaluation of the expression levels of BRAF V600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay

BMC Cancer, 2020
Background The BRAF V600E gene encodes for the mutant BRAFV600E protein, which triggers downstream oncogenic signaling in thyroid cancer. Since most currently available methods have focused on detecting BRAF V600E mutations in tumor DNA, there is limited
Tien Viet Tran, Kien Xuan Dang, Quynh Huong Pham, Ung Dinh Nguyen, Nhung Thi Trang Trinh, Luong Van Hoang, Son Anh Ho, Ba Van Nguyen, Duc Trong Nguyen, Dung Tuan Trinh, Dung Ngoc Tran, Arto Orpana, Ulf-Håkan Stenman, Jakob Stenman, Tho Huu Ho   +14 more
doaj   +1 more source

Intrathoracic synovial sarcoma with BRAF V600E mutation

Oncotarget, 2023
We report a case of 15-year-old boy with intrathoracic synovial sarcoma who relapsed after standard chemotherapy, surgery and radiotherapy. The molecular analysis of the tumour identified a BRAF V600E mutation at time of progression of relapsed disease under third line systemic treatment.
Russo, Ida, Barresi, Sabina, Di Paolo, Pier Luigi, Di Ruscio, Valentina, Del Baldo, Giada, Serra, Annalisa, Vallese, Silvia, Miele, Evelina, Mastronuzzi, Angela, Alaggio, Rita, Ferrari, Andrea, Milano, Giuseppe Maria   +11 more
openaire   +3 more sources

Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. [PDF]

, 2017
Melanoma is a recalcitrant disease. Melanoma patients with the BRAF-V600E mutation have been treated with the drug vemurafenib (VEM) which targets this mutation.
Chmielowski, Bartosz, Dry, Sarah M, Eilber, Fritz C, Han, Qinghong, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Shukuan, Li, Yunfeng, Miyake, Kentaro, Miyake, Masuyo, Murakami, Takashi, Nelson, Scott D, Russell, Tara A, Tan, Yuying, Unno, Michiaki   +16 more
core   +1 more source

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association

Cell Reports, 2018
Summary: Expression of aberrantly spliced BRAF V600E isoforms (BRAF V600E ΔEx) mediates resistance in 13%–30% of melanoma patients progressing on RAF inhibitors. BRAF V600E ΔEx confers resistance, in part, through enhanced dimerization.
Michael J. Vido, Kaitlyn Le, Edward J. Hartsough, Andrew E. Aplin   +3 more
doaj   +1 more source

Heparanase modulates the prognosis and development of BRAF V600E-mutant colorectal cancer by regulating AKT/p27Kip1/Cyclin E2 pathway

Oncogenesis, 2022
BRAF V600E-mutant colorectal cancer (CRC) is a rare subtype of colorectal cancer with poor prognosis. Compelling evidence indicates that the heparanase (HPSE) gene has multiple functions in cancer, however, its role in BRAF V600E-mutant CRC remains ...
Mengling Liu, Xiaojing Xu, Ke Peng, Pengcong Hou, Yitao Yuan, Suyao Li, Xun Sun, Zhongyi Shi, Jiayu Zhang, Yu Dong, Qing Liu, Luoyan Ai, Li Liang, Lu Gan, Qihong Huang, Yiyi Yu, Tianshu Liu   +16 more
doaj   +1 more source

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival [PDF]

Journal of Clinical Medicine, 2020
Acral melanoma, a distinct form of cutaneous melanoma originating in the glabrous skin of the palms, soles, and nail beds, has a different genetic background from other subtypes of cutaneous melanoma. The roles of oncogenic BRAF mutations of acral melanoma in pathogenesis and patient outcomes have not been fully elucidated.
Takamichi Ito, Yumiko Kaku-Ito, Maho Murata, Kazuhisa Furue, Che-Hung Shen, Yoshinao Oda, Masutaka Furue   +6 more
openaire   +2 more sources

Computational evaluation of potent 2-(1H-imidazol-2-yl) pyridine derivatives as potential V600E-BRAF inhibitors

Egyptian Journal of Medical Human Genetics, 2020
Background V600E-BRAF is a major protein target involved in various types of human cancers. However, the acquired resistance of the V600E-BRAF kinase to the vemurafenib and the side effects of other identified drugs initiate the search for efficient ...
Abdullahi Bello Umar, Adamu Uzairu, Gideon Adamu Shallangwa, Sani Uba   +3 more
doaj   +1 more source